Post

New research · Urology
The Lancet. Oncology · 2d
Randomized trialThe Lancet. Oncology · 2026

SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial.

Giulio Francolini, Vanessa Di Cataldo, Saverio Caini … ARTO Working Group
Read paper
UrologyRandomized trial

Adding SBRT to systemic therapy improves overall survival in prostate cancer.

SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial.

Giulio Francolini et al. · The Lancet. Oncology · 2026
Background

The ARTO trial showed improved early clinical outcomes by adding metastasis-directed therapy (MDT), through stereotactic body radiotherapy (SBRT), to abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer.

Purpose

The aim of this analysis is to explore the long-term impact of MDT on overall survival.

Methods

Were randomly assigned (1:1, using random permuted blocks; stratified by treating centre, Eastern Cooperative Oncology Group performance status, and number of metastases) in an open-label design to androgen deprivation therapy plus oral abiraterone acetate 1000 mg daily with or without SBRT to all sites of metastatic disease (one to five fractions providing a biologically effective dose ≥100 Gy).

n = 157 patients
Results
adding SBRT to systemic therapy lowered the risk of death
n = 157 patients
More results

Between Jan 2, 2019, and Sept 7, 2022, 157 patients were randomly assigned to the control (n=82) and experimental (n=75) groups.

More results

Most common grade 3-4 adverse events recorded were infectious complications (five in the control group vs zero in the experimental group) and cardiovascular disorders (three in the control group vs three in the experimental group).

One treatment-related death occurred in the control group due to myocardial failure.

“
Conclusion

The ARTO trial showed significant benefit in overall survival with the addition of MDT to systemic therapy versus systemic therapy alone.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Review
31.0 months
Combination therapy meant a longer time before the cancer got worse
Study
100% sensitivity and specificity for L. longbeachae
The ImmuView test correctly identified all L. longbeachae infections and those without it
Cohort Study
98%
98% of patients had no significant rectocele after laparoscopic double sacrocolpopexy.
Cohort Study
OR 0.10
Beyond 4000 J/ml, the odds of reintervention are 90% lower.
Cohort Study
SIR 1.67
young bladder cancer survivors have a higher risk of developing second cancers compared to the general population